Sponsored By

FDA Doesnt Object to GRAS Status of Sabinsas Curcumin C3 Complex®

October 15, 2013

1 Min Read
FDA Doesnt Object to GRAS Status of Sabinsas Curcumin C3 Complex®

EAST WINDSOR, N.J.Sabinsa Corporation has been issued a "No Comment" letter from the U.S. Food and Drug Administration (FDA) regarding the determination that the company's Curcumin C3 Complex® is Generally Recognized As Safe (GRAS).

Since 2009, Sabinsa's Curcumin C3 Complex® has been self-affirmed GRAS after a comprehensive review of safety and toxicology data by an independent panel of scientists of international repute assembled by Soni & Associates, Inc.

"The 'no comment' letter from the FDA was the next logical step in Sabinsa's long history pioneering curcumin's growth," said Muhammed Majeed, Ph.D, Sabinsa's founder. "With the majority of the published studies on curcumin using C3 Complex, it is no wonder it's the preferred ingredient on the market. GRAS status expands the pool of products in which it can be used."

GRAS status allows manufacturers additional freedom to add Curcumin C3 Complex® in a variety of foods and beverages, ranging from baked goods to imitation dairy products and seasonings and flavors.

"Since Sabinsa's Curcumin C3 Complex® is a patented, uniquely produced ingredient, this GRAS status does not extend to competior's products," said Reza Kamarei, Ph.D, Sabina's vice president of science and technology. "This letter applies to only Sabinsa's products, the way it is manufactured and for its specifications, and others can not copy it. If others need to claim their product is FDA affirmed GRAS, then they will need to submit GRAS notifications to FDA."

Subscribe and receive the latest insights on the health and nutrition industry.
Join 37,000+ members. Yes, it's completely free.

You May Also Like